Registrar Communication Prize Winner
Nitrous Oxide in 2010: Who Will Have the Last Laugh? (Part 2)
Southern African Journal of Anaesthesia and Analgesia | Vol 16, No 2 | a414 |
DOI: https://doi.org/10.1080/22201173.2010.10872663
| © 2010 Kim de Vasconcellos
| This work is licensed under CC Attribution 4.0
Submitted: 03 November 2025 | Published: 01 April 2010
Submitted: 03 November 2025 | Published: 01 April 2010
About the author(s)
Kim de Vasconcellos,, South AfricaFull Text:
PDF (523KB)Abstract
As has been alluded to in the first part of this series, nitrous oxide (N2O) is not the known quantity many of us think it is. It appears to be becoming “scientific fashion†among many anaesthetists to view nitrous oxide as an “anaesthetic untouchable†or, at best, a “second rate citizenâ€. I wish to re-examine this conventional wisdom and see how much of it still holds true. In part two of this three part series, the ENIGMA trial will critically appraised, as will nitrous oxide’s claimed haematological, immunological, neurological, cardiovascular, and respiratory effects. Its influence on postoperative nausea and vomiting will also be evaluated.
Keywords
nitroux oxide
Metrics
Total abstract views: 97Total article views: 20
